Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression
- 1 July 1998
- journal article
- review article
- Published by Elsevier in Clinical Biochemistry
- Vol. 31 (5), 335-340
- https://doi.org/10.1016/s0009-9120(98)00045-9
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- The Rapamycin and FKBP12 Target (RAFT) Displays Phosphatidylinositol 4-Kinase ActivityPublished by Elsevier ,1995
- A Putative Sirolimus (Rapamycin) Effector ProteinBiochemical and Biophysical Research Communications, 1994
- Inhibition of Human B Lymphocyte Cell Cycle Progression and Differentiation by RapamycinCellular Immunology, 1994
- A mammalian protein targeted by G1-arresting rapamycin–receptor complexNature, 1994
- ABROGATION BY RAPAMYCIN OF ACCELERATED REJECTION IN SENSITIZED RATS BY INHIBITION OF ALLOANTIBODY RESPONSES AND SELECTIVE SUPPRESSION OF INTRAGRAFT MONONUCLEAR AND ENDOTHELIAL CELL ACTIVATION, CYTOKINE PRODUCTION, AND CELL ADHESION1,2Transplantation, 1994
- Rapamycin: A novel immunosuppressive macrolideMedicinal Research Reviews, 1994
- Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progressionCell, 1993
- Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in YeastScience, 1991
- Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexesCell, 1991
- Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.The Journal of Antibiotics, 1975